{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 40,
  "pageCount": 45,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a split-screen layout to frame the problem from two angles: supply-side shortage and clinical-side risk.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/40",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8ad8d4a-313e-4786-b67b-8192707fe9ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "In 2017, Merck unexpectedly became the sole supplier of TICE BCG in many countries around the world, including the United States. NCCN guidelines as well as AUA, SUO no longer recommend use of BCG therapy in intermediate-risk NMIBC. BCG is rationed and prioritized for high-risk NMIBC patients in many hospitals and clinics. PIVOT-006 is designed to assess cretostimogene in intermediate-risk patients to alleviate the need to prioritize treatment recipients and ration of BCG given its market shortage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "673ad227-e864-47f9-934c-82ff32349285",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "list",
      "text": "Without BCG, radical cystectomy is a treatment option offered to more patients. High readmissions, complications, morbidity and mortality. Affects multiple organ systems (GI, urinary, Sexual). Few patients undergo cystectomy due to preference and comorbidities. BOND-003 is designed to assess cretostimogene in high-risk patients to address patient aversion to removal of their bladder",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e2b9f31-a8c6-4d1d-a201-13071ea5512e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.84,
        "y": 0.7
      },
      "kind": "metric",
      "text": "2% - 5% Mortality Rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09fc473d-5abe-46b0-9cdc-c8c8850a7e93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.52,
        "y": 0.7
      },
      "kind": "metric",
      "text": "26% - 64% Complication Rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4057866c-0eed-4f8a-ba55-e64a6c3ddcb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.68,
        "y": 0.7
      },
      "kind": "metric",
      "text": "20% - 29% Readmission Rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "425f4e0b-0938-409b-b4a9-b126d7e922e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "NCCN Guidelines – Bladder Cancer 2022. Maiboma et al 2021, Eur J Urol 28(28) 1-8. Merck & Co. Press Release – January 27, 2021. Donat et al. European Association of Urology 55(2009) 177-186. Berger et al. Canadian Urological Association July 2019.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98bbb2a4-8e9b-4a12-b2fb-94eb7e199176",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Global BCG Shortage",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ac88291-a937-44f9-a531-c08c114bfef0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.6,
        "y": 0.05
      },
      "kind": "title",
      "text": "Radical Cystectomy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5206e73-2ba8-4ac2-bcc7-160866d0c930",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}